RAD51B and breast cancer: In the group ≥45 years, hypomethylation of CD160_CpG_3 and RAD51B_CpG_3 were significantly associated with increased risk of BC (ORs per -10% methylation = 1.16 and 2.31 respectively, p < 0.015 for both by logistic regression adjusted for age and batch effects, Figure 3B, Table 3).